Evidence map›Paper›PMID 42063698›Full record

ArticleFrontiers in oncology2026

Upregulation of Caveolin-1 in breast cancer and its potential value in distinguishing TNBC from non-TNBC: an immunohistochemical study.

Chao-Qun Wang, Jun-Kang Shao, Yan Wang, Shi-Ping Lu, Zheng-Guo Xu, Chao-Hui Hu, Bi-Fei Huang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chao-Qun WangDepartment of Pathology, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China.
Jun-Kang ShaoDepartment of Pathology, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China.
Yan WangDepartment of Medical Oncology, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China.
Shi-Ping LuDepartment of Pathology, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China.
Zheng-Guo XuDepartment of Pathology, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China.
Chao-Hui HuDepartment of Pathology, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China.
Bi-Fei HuangDepartment of Pathology, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, there are few studies exploring the expression of Caveolin-1 (CAV-1) in breast cancer tissues and its clinicopathological significance using immunohistochemistry (IHC) technology. This study detected the expression of CAV-1 in 300 cases of invasive breast cancer paraffin tissues through IHC, and analyzed the relationship between CAV-1 expression and the clinicopathological characteristics and prognosis of breast cancer patients. Our results showed that the positivity rate of CAV-1 in breast cancer tissues was 10.0% (30/300), significantly higher than that in normal breast tissues (0.0%, 0/58) (

Indexed as

breast cancerCAV-1Caveolin-1immunohistochemistryprognosis

Identifiers

PMID42063698
PMCPMC13124486

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.